Oxford Asset Management’s Astria Therapeutics ATXS Stock Holding History

Oxford Asset Management’s Portfolio ATXS Stock Details ATXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-52,517	Closed	-$687K	–	474
2025 Q4	$687K	Buy	+52,517	New	+$627K	0.25%	130
2020 Q1	–	Sell	-16,295	Closed	-$578K	–	309
2019 Q4	$578K	Sell	16,295 -1,912	-11%	-$60.3K	0.02%	1164
2019 Q3	$590K	Sell	18,207 -5,035	-22%	-$199K	0.01%	1195
2019 Q2	$1.13M	Buy	23,242 +10,827	+87%	+$491K	0.02%	916
2019 Q1	$590K	Buy	+12,415	New	+$421K	0.01%	1143
2018 Q4	–	Sell	-1,194	Closed	-$59K	–	1768
2018 Q3	$59K	Buy	+1,194	New	+$53.6K	﹤0.01%	1650
2018 Q1	–	Sell	-329	Closed	-$29K	–	1602
2017 Q4	$29K	Buy	+329	New	+$38.7K	﹤0.01%	1579

Oxford Asset Management's ATXS Position: Q1 2026 in Review

Oxford Asset Management sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 52,517 shares — an estimated $687K sold.

Oxford Asset Management first reported a position in ATXS in Q4 2017 and held it in 7 quarters. The position peaked at $1.13M in Q2 2019. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.

Oxford Asset Management reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
Oxford Asset Management sold 52,517 Astria Therapeutics shares in Q1 2026, an estimated $687K.
Oxford Asset Management first reported a position in Astria Therapeutics in Q4 2017 and held it in 7 quarters.
Oxford Asset Management's Astria Therapeutics position peaked at $1.13M in Q2 2019.
0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.

Based on Oxford Asset Management's 13F filing for Q1 2026, filed 15 May 2026.